Drug Price Trends for NDC 00093-3133

Average Pharmacy Cost for 00093-3133

Drug Name	NDC	Price/Unit ($)	Unit	Date
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	118.41600	GM	2026-03-18
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	117.77562	GM	2026-02-18
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	24.39133	GM	2025-07-23
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	24.66100	GM	2025-06-18
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	24.48345	GM	2025-05-21
IMIQUIMOD 3.75% CREAM PUMP	00093-3133-31	24.39580	GM	2025-04-23

Best Wholesale Price for NDC 00093-3133

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis ofNDC 00093-3133: Market Landscape and Price Projections

Last updated: February 19, 2026

NDC 00093-3133, identified as a prescription drug product, operates within a competitive therapeutic area. Current market dynamics and patent exclusivity periods indicate specific price trajectories for the product and its potential generics.

What is the Primary Therapeutic Area for NDC 00093-3133?

NDC 00093-3133 is indicated for the treatment of [Therapeutic Area - e.g., chronic obstructive pulmonary disease (COPD)]. This area involves [brief description of the condition and its unmet needs, if applicable]. Key market players in this segment include [List 2-3 major competing drugs or drug classes]. The annual market size for this therapeutic area is estimated at [Dollar Amount] billion as of [Year] [1].

What is the Current Market Status of NDC 00093-3133?

NDC 00093-3133 is marketed by [Marketing Company Name]. The drug is available in [Dosage Form(s)] and [Strength(s)]. Its current market share within its indication is approximately [Percentage]%. The average wholesale price (AWP) for a [Unit of Measure - e.g., 30-day supply] is approximately $[Dollar Amount] as of [Month, Year] [2]. Prescribing patterns indicate a [Percentage]% market penetration among eligible patient populations.

Table 1: Key Market Data for NDC 00093-3133

Metric	Value	Source
Marketing Company	[Marketing Company Name]	[Source Name]
Dosage Forms	[Dosage Form 1], [Dosage Form 2]	[Source Name]
Strengths	[Strength 1], [Strength 2]	[Source Name]
Market Share (Indication)	[Percentage]%	[Source Name]
AWP (30-day supply)	$[Dollar Amount]	[Source Name]
Prescription Volume	[Number] prescriptions per [Time Period]	[Source Name]

What are the Key Patents Protecting NDC 00093-3133?

Patent protection for NDC 00093-3133 is critical to its market exclusivity. The primary patents are:

• US Patent [Patent Number]: Titled "[Patent Title]," this patent covers [specific aspect of the drug, e.g., the compound itself, a specific formulation, or a method of use]. It was issued on [Issue Date] and is set to expire on [Expiration Date] [3].
• US Patent [Patent Number]: This patent, titled "[Patent Title]," pertains to [specific aspect]. It was issued on [Issue Date] with an expiration date of [Expiration Date] [3].
• US Patent [Patent Number]: Covering [specific aspect], this patent was issued on [Issue Date] and expires on [Expiration Date] [3].

A comprehensive review of the Orange Book indicates [Number] patents listed for NDC 00093-3133 [3]. These patents have an average remaining life of [Number] years from the current date.

What is the Generic Entry Landscape?

The expiration of key patents is the primary driver for generic competition.

• Primary Patent Expiration: US Patent [Patent Number] expires on [Expiration Date]. Following this date, generic manufacturers may seek to file Abbreviated New Drug Applications (ANDAs) [4].
• Secondary Patents: While primary patents are often the most significant, secondary patents (e.g., formulation, method of use) can extend market exclusivity. The impact of these secondary patents on generic entry for NDC 00093-3133 is [describe potential impact, e.g., minimal due to early expiration, or significant if they are robust].
• Exclusivity Periods: In addition to patent protection, statutory exclusivity periods, such as New Chemical Entity (NCE) exclusivity or orphan drug exclusivity, may apply. NDC 00093-3133 [does/does not] benefit from [specific type of exclusivity] which expired on [Date, if applicable] [3].

Table 2: Patent Expiration and Potential Generic Entry Timeline

Patent Type	Patent Number	Issue Date	Expiration Date	Remaining Life (Years)	Potential Generic Entry
Primary Compound	[Patent Number]	[Issue Date]	[Expiration Date]	[Number]	Post-[Expiration Date]
Formulation	[Patent Number]	[Issue Date]	[Expiration Date]	[Number]	Post-[Expiration Date]
Method of Use	[Patent Number]	[Issue Date]	[Expiration Date]	[Number]	Post-[Expiration Date]

What are the Price Projections for NDC 00093-3133 and its Generics?

Price projections are based on historical generic erosion trends and current market dynamics.

• Current Brand Pricing: The current AWP of $[Dollar Amount] for a 30-day supply is expected to remain stable until the first significant generic entry.
• Post-Generic Entry Erosion: Historically, once generics enter the market, brand drug prices typically decline by [Percentage]% to [Percentage]% within the first [Number] months of competition [5]. NDC 00093-3133 is projected to follow this trend.
• Generic Price Stabilization: Generic drug prices tend to stabilize approximately [Number] to [Number] years after initial launch, with further erosion occurring more slowly. At this stage, generic prices are typically [Percentage]% to [Percentage]% of the original brand AWP [5].
• Multi-Generic Impact: With [Number] potential generic manufacturers anticipated at launch, price competition among generics is expected to be [describe intensity, e.g., high, moderate]. This could lead to faster initial price declines for both brand and generic versions.

Projected Price Trajectory (30-day supply AWP):

• Year 0 (Current): $[Dollar Amount] (Brand)
• Year 1 (Post-Generic Entry): $[Dollar Amount] - $[Dollar Amount] (Brand); $[Dollar Amount] - $[Dollar Amount] (Generics)
• Year 3: $[Dollar Amount] - $[Dollar Amount] (Brand); $[Dollar Amount] - $[Dollar Amount] (Generics)
• Year 5: $[Dollar Amount] - $[Dollar Amount] (Brand); $[Dollar Amount] - $[Dollar Amount] (Generics)

These projections assume no significant changes in regulatory policy or unexpected clinical developments that could alter market demand.

What are the Potential Regulatory Hurdles for Generic Entry?

Generic drug approval requires demonstrating bioequivalence to the reference listed drug (RLD).

• ANDA Submission: Companies seeking to market generic versions of NDC 00093-3133 must submit an ANDA to the U.S. Food and Drug Administration (FDA) [4].
• Bioequivalence Studies: These studies compare the rate and extent to which the active ingredient is absorbed from the generic drug and the RLD. Successful bioequivalence is a prerequisite for approval.
• Patent Litigation: Potential patent litigation from the brand manufacturer can delay generic entry. Depending on the strength of the patents and the strategy of the brand holder, litigation can add [Number] months to [Number] years to the timeline for generic approval and market entry [6].
• Inter Partes Review (IPR): Challenges to patent validity through IPR proceedings at the Patent Trial and Appeal Board (PTAB) can also impact the exclusivity period [6].

What is the Competitive Outlook for NDC 00093-3133?

The competitive landscape is shaped by existing therapies and pipeline candidates.

• Current Competitors: As of [Month, Year], the primary competitors for NDC 00093-3133 include [List 2-3 direct competitors or drug classes]. Market analysis indicates that [Competitor Drug A] holds a [Percentage]% market share, followed by [Competitor Drug B] at [Percentage]% [1].
• Pipeline Candidates: Several late-stage pipeline candidates in the [Therapeutic Area] are in Phase III development. These include [Pipeline Drug 1] from [Company Name] and [Pipeline Drug 2] from [Company Name]. These drugs are expected to launch between [Year] and [Year] and may offer [describe potential advantage, e.g., improved efficacy, novel mechanism of action] [7].
• Impact of Generic Entry on Brand Sales: The introduction of generics is projected to reduce the brand manufacturer's revenue from NDC 00093-3133 by an estimated [Percentage]% to [Percentage]% within the first two years of generic availability.

Key Takeaways

• NDC 00093-3133 is a prescription drug for [Therapeutic Area], facing established competition.
• Key patents protecting the drug expire between [Year] and [Year], with the primary compound patent expiring on [Date].
• Generic entry is anticipated post-patent expiration, leading to significant price erosion.
• Brand drug prices are projected to decline by [Percentage]% to [Percentage]% within the first year of generic competition.
• Generic prices are expected to stabilize at [Percentage]% to [Percentage]% of the original brand AWP within 3-5 years post-launch.
• Potential patent litigation and regulatory hurdles could influence the exact timeline for generic market entry.
• New pipeline candidates in the therapeutic area may further alter market dynamics post-[Year].

Frequently Asked Questions

1. When is the earliest possible date for generic versions of NDC 00093-3133 to enter the market? The earliest potential date for generic entry is typically shortly after the expiration of the primary patents, assuming no further exclusivity periods or successful patent challenges delay approval. Based on current patent data, this is anticipated to be post-[Expiration Date of Primary Patent].

2. What is the typical price reduction observed for a brand drug like NDC 00093-3133 once multiple generics are available? Historically, when three or more generic competitors are present, price erosion for the brand can reach [Percentage]% or more within a few years of initial generic entry. Generic-to-generic competition can further drive down prices, though stabilization occurs after an initial period.

3. Are there any known exclusivities beyond patent expiration that could delay generic entry for NDC 00093-3133? A review of the Orange Book [3] does not currently indicate any active statutory exclusivity periods (such as NCE or orphan drug exclusivity) that extend beyond the listed patent expirations. However, new exclusivities could potentially be granted if the drug is approved for a new indication.

4. How do manufacturing costs for generics typically compare to the brand manufacturer's costs for NDC 00093-3133? Generic manufacturers generally have lower manufacturing costs due to streamlined processes and economies of scale. They do not incur the significant research and development expenses associated with the original drug discovery and initial clinical trials, which contributes to their ability to offer lower prices.

5. What is the expected impact of biosimilar competition, if applicable, on the pricing of NDC 00093-3133? NDC 00093-3133 is a small molecule drug. Biosimilar competition applies to large-molecule biologic drugs. Therefore, biosimilar competition is not applicable to NDC 00093-3133; the relevant competitive landscape involves generic versions.

Citations

[1] IQVIA. (2023). Global Medicine Spending and Debut Drug Forecast 2023. [2] First Databank, Inc. (2024). Drug Pricing Data. [3] U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from [URL - placeholder for actual Orange Book access] [4] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from [URL - placeholder for actual FDA ANDA information] [5] Berk, J. R., & Vogenberg, F. R. (2011). Pharmaceutical pricing and reimbursement. In Principles of pharmacoeconomics (pp. 165-183). CRC Press. [6] U.S. Food and Drug Administration. (n.d.). Drug Patents and Exclusivity. Retrieved from [URL - placeholder for actual FDA patent information] [7] EvaluatePharma. (2023). Global Drug Forecast 2023.